SA
CLDI logo
Calidi Biotherapeutics, Inc.(CLDI)
Closing price · checked 9:33 PM ETAbout this dataData status
$0.53▼-0.03 (-5.79%)
Pre-Market:$0.48-0.05 (-9.24%)· 9:33 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average (VIX 22.1)

Overview →

Calidi Biotherapeutics, Inc. focuses on developing innovative immunotherapy treatments for cancer, leveraging its proprietary platform for oncolytic virus therapy. The company operates primarily in the United States, with a pipeline that includes candidates targeting various solid tumors, which positions it uniquely in the competitive landscape of biotechnology.

HealthcareBiotechnologylow - The company has high fixed costs associated with R&D and clinical trials, with limited revenue generation at this stage.

Business Overview

01Research grants and collaborations with pharmaceutical companies - 100%

Calidi generates revenue primarily through research grants and collaborations with larger pharmaceutical firms, which provide funding in exchange for access to its proprietary technologies. The company has a competitive advantage due to its unique approach to oncolytic virus therapy, which has shown promise in preclinical studies, potentially allowing for higher pricing power once products reach commercialization.

What Moves the Stock

Progress in clinical trials for its oncolytic virus therapies

Partnership announcements with larger pharmaceutical companies

Regulatory approvals from the FDA for new therapies

Market sentiment regarding the biotechnology sector

Watch on Earnings
Clinical trial milestones achievedPartnership revenue from collaborationsCash burn rate

Risk Factors

Regulatory changes affecting drug approval processes

Technological disruption from competing therapies

Emerging therapies from competitors in the immunotherapy space

Potential for larger pharmaceutical companies to develop similar treatments

High cash burn rate with negative free cash flow

Limited revenue generation leading to reliance on external funding

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The biotechnology sector can be sensitive to economic cycles, as funding for R&D may be impacted during downturns.

Interest Rates

Interest rates affect Calidi's financing costs for R&D and clinical trials. Higher rates could increase the cost of capital, impacting future funding and valuations.

Credit

minimal - The company has a manageable debt-to-equity ratio of 0.46, indicating limited reliance on credit.

Live Conditions
S&P 500 FuturesDow Jones FuturesRussell 2000 Futures

Profile

growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.

high - The stock has shown significant volatility, with a 1-year return of -98.0%.

Key Metrics to Watch
Clinical trial success rates
Funding secured from partnerships
Cash runway (months until funding is needed)
Market sentiment in the biotechnology sector
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.